Morra E - Search Results

1

Low efficacy of thalidomide in improving response after induction in multiple myeloma patients who are candidates for high-dose therapy.

Corso A, Mangiacavalli S, Barbarano L, Montalbetti L, Mazzone A, Fava S, Varettoni M, Zappasodi P, Morra E, Lazzarino M. Corso A, et al. Among authors: morra e. Leuk Res. 2008 Jul;32(7):1085-90. doi: 10.1016/j.leukres.2007.11.011. Epub 2007 Dec 21. Leuk Res. 2008. PMID: 18096226

2

The VAD-DCEP sequence is an effective pre-transplant therapy in untreated multiple myeloma.

Corso A, Barbarano L, Zappasodi P, Cairoli R, Alessandrino EP, Mangiacavalli S, Ferrari D, Fava S, Fiumanò M, Frigerio G, Isa L, Luraschi A, Klersy C, De Paoli A, Vergani C, Banfi L, Perego D, Ucci G, Pinotti G, Savarè M, Uziel L, Vismara A, Morra E, Lazzarino M. Corso A, et al. Among authors: morra e. Haematologica. 2004 Sep;89(9):1124-7. Haematologica. 2004. PMID: 15377474 Clinical Trial.

3

Limited feasibility of double transplant in multiple myeloma: results of a multicenter study on 153 patients aged <65 years.

Corso A, Mangiacavalli S, Barbarano L, Alessandrino EP, Cairoli R, Morra E, Lazzarino M; HOST Group. Corso A, et al. Among authors: morra e. Cancer. 2007 Jun 1;109(11):2273-8. doi: 10.1002/cncr.22660. Cancer. 2007. PMID: 17440982 Free article.

4

Long-term outcome in relapsed and refractory multiple myeloma treated with thalidomide. Balancing efficacy and side-effects.

Corso A, Zappasodi P, Barbarano L, Petrucci MT, Palumbo A, Caravita T, Mangiacavalli S, Cafro AM, Varettoni M, Gay F, Morra E, Lazzarino M. Corso A, et al. Among authors: morra e. Leuk Res. 2009 Sep;33(9):e145-9. doi: 10.1016/j.leukres.2009.03.015. Epub 2009 Apr 16. Leuk Res. 2009. PMID: 19375164

5

Bortezomib plus dexamethasone can improve stem cell collection and overcome the need for additional chemotherapy before autologous transplant in patients with myeloma.

Corso A, Barbarano L, Mangiacavalli S, Spriano M, Alessandrino EP, Cafro AM, Pascutto C, Varettoni M, Bernasconi P, Grillo G, Carella AM, Montalbetti L, Lazzarino M, Morra E. Corso A, et al. Among authors: morra e. Leuk Lymphoma. 2010 Feb;51(2):236-42. doi: 10.3109/10428190903452826. Leuk Lymphoma. 2010. PMID: 20001242 Clinical Trial.

6

Efficacy, toxicity and feasibility of a shorter schedule of DCEP regimen for stem cell mobilization in multiple myeloma.

Corso A, Mangiacavalli S, Nosari A, Castagnola C, Zappasodi P, Cafro AM, Astori C, Bonfichi M, Varettoni M, Rusconi C, Troletti D, Pascutto C, Morra E, Lazzarino M; HOST Group. Corso A, et al. Among authors: morra e. Bone Marrow Transplant. 2005 Dec;36(11):951-4. doi: 10.1038/sj.bmt.1705166. Bone Marrow Transplant. 2005. PMID: 16184179 Clinical Trial.

7

Dose-dense R-CHOP-14 supported by pegfilgrastim in patients with diffuse large B-cell lymphoma: a phase II study of feasibility and toxicity.

Brusamolino E, Rusconi C, Montalbetti L, Gargantini L, Uziel L, Pinotti G, Fava S, Rigacci L, Pagnucco G, Pascutto C, Morra E, Lazzarino M. Brusamolino E, et al. Among authors: morra e. Haematologica. 2006 Apr;91(4):496-502. Epub 2006 Mar 15. Haematologica. 2006. PMID: 16537117 Clinical Trial.

8

DCEP chemotherapy followed by a single, fixed dose of pegylated filgrastim allows adequate stem cell mobilization in multiple myeloma patients.

Zappasodi P, Nosari AM, Astori C, Ciapanna D, Bonfichi M, Varettoni M, Mangiacavalli S, Morra E, Lazzarino M, Corso A. Zappasodi P, et al. Among authors: morra e. Transfusion. 2008 May;48(5):857-60. doi: 10.1111/j.1537-2995.2007.01621.x. Epub 2008 Feb 1. Transfusion. 2008. PMID: 18248573 Clinical Trial.

9

A combination of dexamethasone, cyclophosphamide, etoposide, and cisplatin is less toxic and more effective than high-dose cyclophosphamide for peripheral stem cell mobilization in multiple myeloma.

Corso A, Arcaini L, Caberlon S, Zappasodi P, Mangiacavalli S, Lorenzi A, Rusconi C, Troletti D, Maiocchi MA, Pascutto C, Morra E, Lazzarino M. Corso A, et al. Among authors: morra e. Haematologica. 2002 Oct;87(10):1041-5. Haematologica. 2002. PMID: 12368158

10

The role of systemic high-dose cytarabine in the treatment of central nervous system leukemia. Clinical results in 46 patients.

Morra E, Lazzarino M, Brusamolino E, Pagnucco G, Castagnola C, Bernasconi P, Orlandi E, Corso A, Santagostino A, Bernasconi C. Morra E, et al. Cancer. 1993 Jul 15;72(2):439-45. doi: 10.1002/1097-0142(19930715)72:2<439::aid-cncr2820720220>3.0.co;2-4. Cancer. 1993. PMID: 8319175 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

356 results

Search Page

Filters